---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024981"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:09:54.854871+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q3 rev down 14% to $66M; raises FY22 revenue guidance to $460-480M

## Summary
- Total revenue $66M (down 14% YoY); Foundry $25M (down 29%), Biosecurity $42M (down 3%).
- Operating loss $(653)M includes $563M stock-based comp; Adj EBITDA $(70)M vs $(18)M prior year.
- Added 15 new Cell Programs (50% growth); cash & equivalents over $1.3B.
- Completed Zymergen, Bayer West Sac, Altar, and Circularis acquisitions in October.
- FY22 guidance raised: total rev $460-480M (from $425-440M), Biosecurity at least $310M.

## SEC filing metadata
- accession: 0000950170-22-024981
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/dna-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024981
- JSON: https://secwatch.observer/filing/0000950170-22-024981.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024981.txt

## Key facts
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported third quarter ended September 30, 2022 results: revenue Third quarter 2022 Total revenue of $66 million.
  - Period: third quarter ended September 30, 2022
  - Revenue: Third quarter 2022 Total revenue of $66 million
  - Result: reported results
  source text: Third quarter 2022 Total revenue of $66 million, down from $78 million in the comparable prior year period, a decrease of 14%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm
- Earnings Releases
  Ginkgo Bioworks Holdings, Inc. reported full year 2022 results: revenue $460 – $480 million. Guidance raised.
  - Period: full year 2022
  - Revenue: $460 – $480 million
  - Guidance: raised
  - Result: guidance update
  source text: Ginkgo further revised its expectation for Total revenue from $425 – $440 million to $460 – $480 million in 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1830214/000095017022024981/0000950170-22-024981-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.